Patent intelligence · US
US 7348314
Compositions and methods for inhibiting viral replication
Compositions and methods for inhibiting viral replication
Patent details — US 7348314
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2008
- Expiration
- Mar 20, 2028
- Applicant
- Alnylam Europe AG
- Claims
- 3
- CPC classes
- A61P, A61P35/00
Quick answer
US 7348314 (Compositions and methods for inhibiting viral replication) is held by Alnylam Europe AG. Status: granted. Granted Mar 25, 2008. Expires Mar 20, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alnylam Europe AG
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61P, A61P35/00
More from Alnylam Europe AG
Related pharmaceutical patents in our USPTO index.
-
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12397013
Extrahepatic delivery
granted -
US 12385043
Modified double-stranded RNA agents
granted -
US 12385044
Modified double-stranded RNA agents
granted -
US 12378553
Modified double-stranded RNA agents
granted -
US 12364762
Biodegradable lipids for the delivery of active agents
granted -
US 12350338
Biodegradable lipids for the delivery of active agents
granted
Frequently asked questions
What is US patent 7348314?
US 7348314 (Compositions and methods for inhibiting viral replication) is held by Alnylam Europe AG. Status: granted. Granted Mar 25, 2008. Expires Mar 20, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7348314?
Alnylam Europe AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.
When does US 7348314 expire?
Our index shows an expiration date of Mar 20, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.